Brief: Evelo Biosciences Reports Positive Topline Clinical Data In Phase 1B Trial Of EDP1815 In Atopic Dermatitis

Evelo Biosciences

09/12/2020 12:03

Dec 9 (Reuters) - Evelo Biosciences Inc  EVLO.O :
    * EVELO BIOSCIENCES REPORTS POSITIVE TOPLINE CLINICAL DATA
IN
PHASE 1B TRIAL OF EDP1815 IN ATOPIC DERMATITIS
    * EVELO BIOSCIENCES INC - TREATMENT WITH EDP1815
DEMONSTRATES
STATISTICALLY AND CLINICALLY SIGNIFICANT IMPROVEMENT IN MEAN
EASI AND IGA* BSA SCORES
    * EVELO BIOSCIENCES INC - EDP1815 WAS OBSERVED TO BE WELL
TOLERATED WITH NO SERIOUS ADVERSE EVENTS
    * EVELO BIOSCIENCES INC -  LOOK FORWARD TO SHARING COMPLETE
DATASET FROM PHASE 1B TRIAL IN EARLY 2021

Source text for Eikon:  ID:nGNE2MDq8b 
Further company coverage:  EVLO.O 

 ((Reuters.Briefs@thomsonreuters.com;))